Downregulation of TNF-α and VEGF expression by Sp1 decoy oligodeoxynucleotides in mouse melanoma tumor

Gene Therapy

Volumn 10, Issue 23, 2003, Pages 1992-1997

  Novak, E M ^a   Metzger, M ^b   Chammas, R ^b,c   da Costa, M ^b   Dantas, K ^a   Manabe, C ^a   Pires, J ^a   de Oliveira, A C ^a   Bydlowski, S P ^a,b  

^a Res and Molecular Biology Division   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Center for Cell Therapy and Regional Blood Center   (Brazil)

Author keywords

Angiogenesis; Gene therapy; Melanoma; Transcription factor; VEGF splicing

Indexed keywords

ANGIOGENESIS INHIBITOR; CD34 ANTIGEN; ISOPROTEIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CANCER TRANSPLANTATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MELANOMA; MICROENVIRONMENT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; GENE EXPRESSION REGULATION; GENE THERAPY; MELANOMA; MICE; MICE, INBRED C57BL; NECROSIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; SKIN NEOPLASMS; SP1 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; MURINAE;

EID: 0242351063     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302111     Document Type: Article

References (46)

1. Folkman J, Klagsburn M. Angiogenic factors. Science 1987; 235: 442-447.
2. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 70: 185-188.
3. Hanahan D, Folkman J. Pattern and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
4. Pober JS et al. Overlapping patterns of activation of human endothelial cells by interleukin I, tumor necrosis factor and immune interferon. J Immunol 1986; 137: 1893-1896.
5. Ramasamy S, Lipke DW, McClain CJ, Hennig B. Tumor necrosis factor reduces proteoglycan synthesis in cultured endothelial cells. J Cell Physiol 1995; 162: 119-126.
6. Chung AS, Yoon SO, Park SJ, Yun CH. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003; 36: 128-137.
7. Folkman J et al. A heparin-binding angiogenic protein-basic fibroblast is stored within basement membrane. Am J Pathol 1988; 130: 393-400.
8. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934.
9. Frater-Schroder M et al. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987; 84: 5277-5281.
10. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996; 32A: 2413-2422.
11. Grunstein J et al. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999; 59: 1592-1598.
12. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
13. Stephan CC, Brock TA. Vascular endothelial growth factor a multifunctional polypeptide. Puerto Rico Health Sci J 1996; 15: 169-178.
14. Tischer E et al. The human gene for vascular endothelial growth factor: Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266: 11947-11954.
15. Shima DT et al. The mouse gene for vascular endothelial growth factor: Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptonal regulatory sequences. J Biol Chem 1996; 271: 3877-3883.
16. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrinol Rev 1992; 13: 18-32.
17. Claffey KP, Senger DR, Spiegelman BM. Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. Biochim Biophys Acta 1995; 1246: 1-9.
18. Leung D et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
19. Plouer J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by ArT20 cells. EMBO J 1989; 8: 3801-3807.
20. Grunstein J et al. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol Cell Biol 2000; 20: 7282-7291.
21. Wang S, Wang W, Wesley R, Danner R. A Sp1 binding site of the tumor necrosis factor α promoter functions as a nitric oxide response element. J Biol Chem 1999; 274: 33190-33193.
22. 1 promoters by transcription factors Sp1. Gene 1993; 129: 223-228.
23. Molander C et al. Sp1 is a key regulator of the PDGF beta-receptor transcription. Mol Biol Rep 2001; 28: 223-233.
24. Gonzalez FJ, Lee YH. Constitutive expression of hepatic cytochrome P450 genes. FASEB J 1996; 10: 1112-1117.
25. Pugh BF, Tijan R. Mechanism of transcriptional activation by Sp1: evidence for coactivators. Cell 1990; 61: 1187-1197.
26. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and Krüppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001; 188: 143-160.
27. Roman DG, Toledano MB, Leonard WJ. Sp1 represses IL-2 receptor alpha chain gene expression. New Biol 1990; 7: 642-647.
28. Madsen CS et al. Expression of the smooth muscle myosin heavy chain gene is regulated by a negative-acting GC-rich element located between two positive-acting serum response factor binding element. J Biol Chem 1997; 272: 6332-6340.
29. Ryuto M et al. Induction of vascular endothelial growth factor by tumor necrosis factor α in human glioma cells. J Biol Chem 1996; 271: 28220-28228.
30. 1, and tissue factor and also cell growth and invasion activities. Cancer Res 2000; 60: 6531-6536.
31. Vermemeulen PB et al. Quantification of angiogenesis in solid tumors: an international consensus on the methodology and criteria of evolution. Eur J Cancer 1996; 32: 2474-2484.
32. Hata Y et al. Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence. J Biol Chem 1998; 273: 19294-19303.
33. Luster TA et al. Effects of three Sp1 motifs on the transcription of the FGF-4 gene. Mol Reprod Dev 2000; 57: 4-15.
34. Carè A et al. HOXB7: a key factor for tumor-associated angiogenic switch. Cancer Res 2001; 61: 6532-6539.
35. Meccia E et al. HOXB7 expression is regulated by the transcription factors NF-Y, YY1, Sp1, and USF-1. Biochim Biophys Acta 2003; 1626: 1-9.
36. Yu JL, Rak JW, Klement G, Kerbel R. Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Res 2002; 62: 1838-1846.
37. Houck KA et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267: 26031-26037.
38. Houck KA et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Cell Endocrinol 1991; 5: 1806-1814.
39. Potegens AJG et al. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 1995; 146: 197-209.
40. Redondo P et al. Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine down-regulates VEGF production in vitro. Cytokine 2000; 12: 374-378.
41. Stalmans I et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 2002; 109: 327-336.
42. Nakamura T et al. Molecular strategy using cis-element 'decoy' of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model. Gene Therapy 2002; 9: 488-494.
43. Mann MJ, Dzau J. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 2000; 106: 1071-1075.
44. Morishita R et al. A novel molecular strategy using cis element 'decoy' of E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-5859.
45. Tomita N et al. An oligonucleotides decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro. Am J Physiol 1998; 275: F278-F284.
46. Borgatti M et al. Transcription factor decoy molecules based on a PNA-DNA chimera mimicking Sp1 binding sites. J Biol Chem 2003; 278: 7500-7509.